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For several reasons, including selective pressure from 
overuse of antibiotics, there has been worldwide emergence 
of multidrug-resistant (MDR) bacteria – reports of hospital 
outbreaks resulting from such strains are cause for concern. In 
South Africa, the increased use of carbapenems is driven by 
an increase in cephalosporin and fluoroquinolone resistance 
among extended-spectrum β-lactamase (ESBL)-producing 
Enterobacteriaceae.1 Although extensive published data2 are 
available on antibiotic susceptibility of community-acquired 
respiratory tract pathogens, especially Streptococcus pneumoniae, 
very few data have been documented for Gram-negative 
pathogens such as Acinetobacter baumannii or Pseudomonas 
aeruginosa or for Gram-positive pathogens, particularly 
Staphylococcus aureus. In the past, one private laboratory in 
Johannesburg, which participated in the SENTRY international 
antimicrobial surveillance programme,3 documented the 
prevalence rate of ESBL production in Enterobacter cloacae 
from hospitalised patients at 20% (N = 11/54), and oxacillin 
resistance in blood culture isolates of nosocomially acquired 
S. aureus at 40%.4 These results may not be representative of 
the rest of the private hospitals in South Africa. This prompted 
a nationwide study in clinical private practice to examine 
the susceptibility of important invasive Gram-negative 
pathogens and S. aureus, including ESBL production in selected 
Enterobacteriaceae.
Materials and methods
Collaborating centres
The study was conducted from 1 January 2006 to 30 June 2006. 
Twelve laboratories of 7 private pathology practices in all the 
private hospitals in Johannesburg, Pretoria, Durban, Cape 
Town and Bloemfontein participated in the survey, namely 
Drs Bouwer and Partners (Ampath), Drs Dietrich and Voigt 
(Pathcare), Drs du Buisson, Bruinette and Partners (Ampath), 
Drs Mauf and Partners (Lancet), Drs Swart and Marais 
(Ampath), Drs van Rensburg Pathologists, and Drs Vermaak 
and Partners. The participants from these laboratories are listed 
in the Acknowledgements.
Bacterial isolates and susceptibility testing
Inclusion criteria for bacterial isolates were any isolate cultured 
from blood of hospitalised patients irrespective of whether 
infections were regarded as being community or nosocomially 
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Objectives. The National Antimicrobial Surveillance Forum is a 
continuous surveillance organisation comprising all academic/
public and private sector laboratories in South Africa. 
Methods. The antibiotic susceptibility of blood culture 
isolates of Escherichia coli, Klebsiella pneumoniae, Enterobacter 
species, Pseudomonas aeruginosa, Acinetobacter baumannii and 
Staphylococcus aureus from patients in private hospitals in five 
major centres were investigated. Antimicrobial susceptibility 
tests were performed by 12 participating laboratories according 
to the Clinical and Laboratory Standards Institute (CLSI) 
guidelines. Extended-spectrum β-lactamase (ESBL) production 
was determined in selected species of Enterobacteriaceae 
irrespective of source.
Results. The overall prevalence of ampicillin resistance in blood 
culture isolates of E. coli (N = 471) was 84%, and 20% were 
resistant to the fluoroquinolones. Considerable geographical 
differences were noted between the centres with regard to the 
K. pneumoniae (N = 636) resistance rates for ceftriaxone and/or 
cefotaxime (39 - 87%). The most active agents in the Enterobacter 
spp. (N = 244) were imipenem/meropenem, ertapenem, 
ciprofloxacin, levofloxacin and cefepime, with 100%, 94%, 
88%, 87% and 80% susceptibility, respectively. Carbapenem 
resistance in P. aeruginosa (N = 382) varied between 42% and 
45%, and in the case of A. baumannii (N = 190) resistance 
varied between 32% and 33% for meropenem and imipenem 
respectively. The nationwide incidence of oxacillin resistance 
in S. aureus (N = 629) was 36%. Overall, the prevalence of ESBL 
production among all isolates of K. pneumoniae was 26% (N =  
7 514), while in Enterobacter spp. it was 12% (N = 4 031) and in 
E. coli 5% (N = 28 412).
Conclusions. The data highlight the widespread problem of 
antibiotic resistance among important bacteraemic pathogens 
in private institutions in South Africa. Continued surveillance 
is vital to guide appropriate empirical therapy for invasive 
infections. 
S Afr Med J 2007; 97: 273-279.
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acquired. Duplicate isolates from the same patient were 
avoided. Isolation and identification were done according to 
standard methods. All species of Enterobacter were included 
in the study. Participating laboratories (9/12) performed disc 
diffusion susceptibility testing according to the Clinical and 
Laboratory Standards Institute (CLSI) guidelines.5 Quality 
control strains recommended by the CLSI were used and 
results of testing were accepted if results of control strains 
were within published limits. The other 3 laboratories 
reported susceptibility results using the automated Vitek 2 
system (BioMerieux, Marcy L’Etoile, France). External quality 
control was performed on a regular basis (National Health 
Laboratory Service Quality Assessment Programme, External 
Quality Assessment Unit, National Institute for Communicable 
Diseases, Sandringham, Johannesburg, South Africa as 
well as Thistle Quality Assurance Programme, Northcliff, 
Johannesburg, South Africa).
The antibiotics tested for lactose-fermentative Gram-negative 
bacilli were ampicillin, cefuroxime, ceftriaxone and/or 
cefotaxime, cefepime, amoxicillin-clavulanate, piperacillin-
tazobactam, ciprofloxacin, levofloxacin, ertapenem, imipenem 
and meropenem. Aminoglycoside susceptibility was not 
reported. In the case of non-lactose fermentative isolates the 
following were tested: ceftazidime, cefepime, piperacillin-
tazobactam, amikacin, tobramycin, ciprofloxacin, levofloxacin, 
imipenem and meropenem. For S. aureus isolates, cefoxitin or 
oxacillin (reported as cloxacillin), rifampicin, trimethoprim/
sulfamethoxazole, fusidic acid, gentamicin, teicoplanin, 
vancomycin and linezolid were tested. 
In most laboratories (8/12), teicoplanin and vancomycin 
susceptibility of S. aureus was determined by disc diffusion 
using the CLSI parameters for teicoplanin.5 One laboratory 
used brain-heart-infusion agar screening with vancomycin (6 
μg/ml) and with teicoplanin (12 μg/ml) to test these isolates 
for glycopeptide resistance, while another 3 laboratories 
used the automated Vitek system. In all laboratories, reduced 
susceptibility was confirmed by determining minimum 
inhibitory concentrations (MICs) using teicoplanin and/or 
vancomycin E-tests (AB Biodisk, Solna, Sweden). 
ESBL production was determined in all strains of Klebsiella 
pneumoniae, Enterobacter spp. and Escherichia coli over the study 
period irrespective of the source and whether the isolates 
were regarded as being community or hospital acquired. The 
production was determined using the Vitek automated system 
in 3 laboratories and the double-disc synergy test in the rest.6 
Once susceptibility testing was completed, data from each 
laboratory were sent to a central data collection point where 
collation and intra- and intercity comparisons were performed. 
Patient names and hospital and laboratory numbers were not 
referred to at any stage and therefore patient consent was not 
sought as surveillance data were submitted anonymously. 
Results
Over the study period a total of 2 552 blood culture isolates 
were tested.  Twenty-eight thousand four hundred and twelve 
isolates of E. coli, 7 514 K. pneumoniae and 4 031 Enterobacter 
spp. cultured from various sources, were tested for ESBL 
production.
E. coli
Table I shows the susceptibility of 471 isolates of E. coli. Eighty-
four per cent of the isolates were resistant to ampicillin, with 
overall cefuroxime, ceftriaxone and cefepime resistance of 11%, 
10% and 6% respectively. Of the beta-lactam/beta-lactamase 
inhibitor combinations, piperacillin-tazobactam was the most 
active, with 89% susceptible to this agent, while susceptibility 
to co-amoxiclav was 63%. Ciprofloxacin resistance ranged 
from 12% to 26% (Fig. 1), with a nationwide average of 20% 
(95/471) and 19% (90/471) for ciprofloxacin and levofloxacin, 
respectively. No resistance to ertapenem, imipenem and 
meropenem was detected.
K. pneumoniae
Of 636 isolates isolated, 98% were ampicillin resistant (Table 
I).  Cephalosporin resistance was high: 52% (330/636), 46% 
(292/636) and 44% (279/636) with regard to cefuroxime, 
ceftriaxone and cefepime, respectively. Resistance to 
piperacillin-tazobactam and co-amoxiclav was similar (40% 
and 52%, respectively). Fluoroquinolone resistance was higher 
than in E. coli with 31% (197/636) and 32% (203/636) resistant 
to ciprofloxacin and levofloxacin, respectively. Two per cent of 
the isolates were resistant to ertapenem and none to imipenem 
and meropenem.
Enterobacter spp.
As shown in Table I, antibiotic resistance in 244 isolates of E. 
cloacae and other species was also high. All the strains were 
resistant to ampicillin. The most active cephalosporin was 
cefepime, with 80% susceptibility. Activity of levofloxacin and 
ciprofloxacin was similar (87 - 88% susceptibility, respectively). 
Piperacillin-tazobactam resistance was 30% (73/244) overall, 
with some centres reporting up to 79% resistance (Fig. 1). 
Six per cent of isolates were resistant to ertapenem, while no 
resistance to imipenem and meropenem was detected.
P. aeruginosa
Overall, carbapenem resistance in isolates of P. aeruginosa 
(N = 382) varied between 42% and 45% for meropenem and 
imipenem, respectively (Table I). Ceftazidime resistance 
was 45%; a similar prevalence of resistance to cefepime was 
noted (53%). Resistance to piperacillin-tazobactam varied 
between 21% and 61%, with an average of 48% (183/382) 
(Fig. 2). Fluoroquinolone resistance was similar, with 46% 
(175/382) resistant to both ciprofloxacin and levofloxacin. Of 
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the aminoglycosides tested, amikacin was more active than 
tobramycin (52% versus 47% susceptible respectively).
A. baumannii
The most active agent in the 190 isolates was not a carbapenem 
but tobramycin, with 81% testing susceptible (Table I). As 
depicted in Fig. 2, carbapenem resistance ranged between 
centres from 3% to 72%, with an overall prevalence of 32% 
(60/190) and 33% (62/190) for meropenem and imipenem, 
respectively. Activity of the cephalosporins, piperacillin-
tazobactam and the fluoroquinolones was similar; resistance 
ranged from 43% for ceftazidime and cefepime to 31% for 
levofloxacin.
Table I. Antibiotic resistance (%) among bacteraemic strains of selected pathogens in private practice in South Africa,  
January - June 2006
          E. coli                   K. pneumoniae                         Enterobacter spp.
          (N = 471)                  (N = 636)                          (N = 244)
                     %                                       %                         %
Antibiotic           N        Overall       Range                       N        Overall       Range                  N        Overall       Range
         
Ampicillin            396         84          78 - 90               623         98            88 - 100                  244         100        -
Cefuroxime             52          11            5 - 37               330         52            31 - 62                  195           80       50 - 100
Ceftriaxone/cefotaxime            47         10            3 - 14               293         46            13 - 61                  110           45       28 - 100
Cefepime              28            6            0 - 11               280         44            12 - 59                    49           20       15 - 25
Co-amoxiclav             78         37          15 - 52               330         52            22 - 61                  237           97       89 - 100
Piperacillin-tazobactam            52         11            4 - 18               254         40            26 - 53                    73           30        9  - 79
Ciprofloxacin             95         20          12 - 26               197         31               0 - 49                    29           12        8  - 21
Levofloxacin             90          19            9 - 31               203         32               0 - 49                    32           13        8  - 22
Ertapenem               0           0                -                 12           2              0 - 10                    15             6        4  - 8
Imipenem               0           0                -                   0           0                -                            0             0           -
Meropenem               0           0                -                   0           0                -                            0             0           -
         P. aeruginosa   A. baumannii
         (N = 382)      (N = 190)
     %                 %
            N        Overall       Range       N  Overall      Range
Ceftazidime            172         45          11 - 90           82           43          21 - 81
Cefepime             202         53          21 - 70           82           43          10 - 83
Piperacillin-tazobactam           183         48          21 - 61           80           42          14 - 83
Ciprofloxacin            176         46          30 - 67           68           36          10 - 75
Levofloxacin            176         46          21 - 67           59           31          10 - 75
Amikacin             183         48          11 - 67           55           29            7 - 70
Tobramycin            202         53           11  - 100       36           19            7 - 40
Imipenem            172         45          23 - 63            63           33            3 - 72
Meropenem            160         42          15 - 64           61           32            3 - 72
                                                                       S. aureus
                                                                      (N = 629)
                   %
            N    Overall      Range
Cloxacillin            226         36          29 - 46
Trimethoprim/sulfamethoxazole      182         29            4 - 33
Fusidic acid              19           3            0 - 7
Rifampicin              69         11             3 - 27
Gentamicin              75         12            6 - 20
Teicoplanin               0           0               -
Vancomycin               0           0               -
Linezolid                0           0               -
N = number of strains.
Range = variation between centres.
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S. aureus
The prevalence of oxacillin resistance varied from 29% to 
46% (Fig. 3), with an overall average of 36% (226/629) (Table 
I). Together with teicoplanin, vancomycin and linezolid (for 
which no resistance was detected), fusidic acid had excellent 
activity, with only 3% of the isolates resistant. Rifampicin, 
gentamicin and trimethoprim/sulfamethoxazole resistance was 
documented as 11%, 12% and 29% overall, respectively.
Extended-spectrum β-lactamase production 
As shown in Table II, 26% of K. pneumoniae isolates overall 
produced an ESBL, with detection rates varying between 8% 
and 42% at the different centres. Similarly, ESBL production 
detection in Enterobacter spp. varied, with Cape Town recording 
a prevalence of 27%. Overall, 12% of these isolates produced an 
ESBL. In contrast, the prevalence of ESBL production in E. coli 
was the lowest (5%) of the Enterobacteriaceae tested and did 
not differ significantly between the cities.
Discussion
Overall, the results for E. coli in this study are similar to 
those reported from Europe,7 where up to 23% of invasive 
isolates were resistant to the third-generation cephalosporins. 
Fluoroquinolone resistance was also comparable (19% and 
20% for levofloxacin and ciprofloxacin, respectively).7 The 
rate of ESBL production (5%) is also similar to that reported 
for some European countries. The worldwide emergence of 
novel ESBLs,8 specifically cefotaximases (CTX-M) in E. coli 
predominantly causing urinary tract infections, has not been 
documented in South Africa.8 However, the emergence of 
CTX-M β-lactamases in K. pneumoniae has been described.1 The 
rate of MDR was not determined in this study; Bell et al.9 have 
previously shown the prevalence among bacteraemic isolates 
to be 4%. 
Fig. 1. Antibiotic resistance (%) of bacteraemic strains of fermentative 
Gram-negative bacilli in different centres in private practice in South 
Africa, January - June 2006. (AMP = ampicillin; CXM = cefuroxime; 
CRO/CTX = ceftriaxone/cefotaxime, FEP = cefepime; AMC = co-amoxi-
clav; TZP = piperacillin-tazobactam; ERT = ertapenem, IPM = imipenem; 
MEM = meropenem; CIP = ciprofloxacin; LVX = levofloxacin; Jhb = 
Johannesburg; Pta = Pretoria; Dbn = Durban; CT = Cape Town; Bfn = 
Bloemfontein; N = total number of isolates.)
Fig. 2. Antibiotic resistance (%) of bacteraemic strains of non-fermenta-
tive Gram-negative bacilli in different centres in private practice in South 
Africa, January - June 2006. (CAZ = ceftazidime; FEP = cefepime; TZP 
= piperacillin-tazobactam; AMK = amikacin; TOB = tobramycin; IPM = 
imipenem; MEM = meropenem; CIP = ciprofloxacin; LVX = levofloxacin; 
Jhb = Johannesburg; Pta = Pretoria; Dbn = Durban; CT = Cape Town; Bfn 
= Bloemfontein; N = total number of isolates.)
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The high level of ampicillin (84%) and co-amoxiclav 
resistance (37%) among E. coli isolates generally preclude these 
agents as empirical choices when invasive infections due to this 
pathogen are suspected. Similarly, with 20% fluoroquinolone 
resistance, these antibiotics should probably be reserved for 
directed therapy.  
The high rate of cephalosporin resistance among the blood 
culture isolates of K. pneumoniae (52% for cefuroxime, 46% for 
ceftriaxone or cefotaxime and 44% for cefepime) most probably 
reflects the high overall incidence of ESBL production in this 
species (26%). However, the incidence among blood culture 
isolates specifically is now under investigation. Nationwide, 
piperacillin-tazobactam resistance was 40%. It was recently 
demonstrated10 that the mechanisms of inhibitor-combination 
resistance in ESBL-producing K. pneumoniae (N = 139) in 
Johannesburg is due to modification of outer membrane 
proteins (porin-deficiency) changes in 12 (9%), high-level Bush 
group 2b β-lactamase production in 6 (4%), and oxacillinase 
(OXA)-type enzymes (Bush group type 2d) in 1 isolate 
(0.7%), respectively.10 Inhibitor-resistant (IRT) Bush group 2br 
enzymes were not detected. Fluoroquinolone resistance was 
31% and 32% for ciprofloxacin and levofloxacin, respectively. 
Similarly, among Klebsiella spp. collected from intensive 
care units (ICUs) in Southern and Western Europe in 1998, 
Babini and Livermore11 documented the proportion of ESBL-
producers co-resistant to piperacillin-tazobactam to be 63%, 
with fluoroquinolone resistance 31%. In New York,12 25% of 
non-ESBL-producing isolates of K. pneumoniae were resistant 
to piperacillin-tazobactam and ciprofloxacin, but among ESBL-
producing isolates, 54% and 50% were resistant respectively.
Recently, co-resistance to three unrelated classes of antibiotics 
(trimethoprim/sulfamethoxazole, gentamicin or amikacin, 
and fluoroquinolones) among ESBL-positive Klebsiella spp. 
(N = 139) and E. coli isolates (N = 988) in South Africa were 
reported to be 57% and 72%, respectively.10 The problem of 
drug-resistant K. pneumoniae and E. coli might be exacerbated 
by failure of infection control practices in the community, 
hospitals, long-term care facilities and old-age homes, all of 
which might be important reservoirs for ESBL-containing 
multiple antibiotic-resistant Gram-negative pathogens. 
MDR in these Gram-negatives severely limits therapeutic 
options. Based on the results from most major centres, mild 
to moderate infections due to K. pneumoniae would be best 
treated empirically with ertapenem and in the future with 
tigecycline, reserving imipenem and meropenem for more 
serious bacteraemic cases, particularly those admitted to ICUs.  
To reduce selection pressure on both groups of carbapenems, 
mandatory de-escalation to narrow-spectrum antibiotics (once 
culture and susceptibility become available) is necessary. In 
this regard, few therapeutic options remain because of current 
international practice according to which in the presence of 
ESBL production all penicillin, cephalosporin and aztreonam 
results are edited as resistant irrespective of phenotypic 
susceptibility pattern. 
In contrast, where infections caused by Enterobacter spp. 
are suspected more empirical options besides ertapenem 
or imipenem and meropenem are available. These include 
cefepime and levofloxacin or ciprofloxacin, with 80%, 87% 
and 88% of the isolates respectively being susceptible. The 
susceptibility pattern with regard to cefepime probably 
reflects excellent activity against chromosomal-located 
cephalosporinase (Amp-C)-producing isolates. However, 
caution has been expressed in respect of cefepime use in 
Table II. Incidence (%) of ESBL production (number of isolates) in selected strains of Enterobacteriaceae in private practice in 
South Africa (all sources), January - June 2006
   K. pneumoniae   Enterobacter spp.    E. coli
   % (N)    % (N)      % (N)
Overall   26 (7 514)    12 (4 031)     5 (28 412)
Centre   
Johannesburg  42 (3 010)    11 (1 486)     4 (12 600)
Pretoria  27 (2 244)    10 (1 061)     3 (7 406)
Durban  8 (1 359)      5 (1 093)     4 (5 637)
Cape Town  40 (805)     27 (328)     4 (1 380)
Bloemfontein  15 (96)       6 (63)     12 (1 389)
Fig. 3. Antibiotic resistance (%) of bacteraemic strains of S. aureus in 
different centres in private practice in South Africa, January - June 2006. 
(OXA = oxacillin; SXT = trimethoprim/sulfamethoxazole; FUC = fusidic 
acid; RIF = rifampicin; GEN = gentamicin; TEC = teicoplanin; VAN = 
vancomycin; LZD = linezolid; Jhb = Johannesburg; Pta = Pretoria; Dbn 
= Durban; CT = Cape Town; Bfn = Bloemfontein; N = total number of 
isolates.)
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cases of high-inoculum ceftazidime-resistant Enterobacter 
infections as treatment failures have been described in a 
murine experimental model as well as in the clinical setting.13 
Tazobactam does not inhibit these chromosomal enzymes 
and therefore piperacillin-tazobactam is not appropriate 
for such infections. Similarly, although 55% of invasive 
Enterobacter spp. in this study were susceptible to the third-
generation cephalosporins, these agents should also be 
avoided empirically, as it has been demonstrated that the 
30-day mortality rate of bacteraemic patients with resistant 
infections treated using this group of agents is significantly 
higher than mortality among patients with third-generation 
susceptible Enterobacter bloodstream infections (33.7% v. 18.6%; 
p = 0.021).14 The nationwide prevalence of ESBL production 
in this pathogen was 12%, which is lower than that reported 
previously in hospitalised patients from South Africa.3 One 
possible explanation is that in this study all Enterobacter spp. 
were tested irrespective of whether they were regarded as 
nosocomial or community acquired. In addition, it is clear that 
geographical differences (5 - 27%) exist in private practice in 
South Africa. 
Antibiotic resistance in P. aeruginosa was overall higher than 
in A. baumannii. Carbapenem resistance in the former was 42% 
and 45% for meropenem and imipenem respectively, compared 
with 32% and 33% in A. baumannii.  Similarly, cefepime and 
piperacillin-tazobactam resistance was 53% v. 43% and 48% 
v. 42% for these non-fermentative bacilli, respectively. The 
prevalence of fluoroquinolone resistance was also noted to be 
less in A. baumannii than P. aeruginosa, namely 31% v. 46% for 
levofloxacin and 36% v. 46% for ciprofloxacin, respectively. 
Tobramycin was the most active agent against A. baumannii 
(81% susceptibility). In the present survey the prevalence of 
resistance to antipseudomonal agents in bloodstream isolates of 
P. aeruginosa was considerably higher than reported elsewhere15 
(with resistance to piperacillin 29%, ceftazidime 19%, 
ciprofloxacin 17% and imipenem 15%, respectively) (N = 190). 
Significantly, in the study by Kang et al.15 the 30-day mortality 
rate was 44% (33/75) in patients infected with isolates 
resistant to any of the antipseudomonal agents, compared 
with 33.9% (39/115) in patients with strains susceptible to all 
antipseudomonal antibiotics (p = 0.161). Patients infected with 
imipenem-resistant strains had the highest mortality. Clearly, 
the impact of outcome in our setting needs to be determined. 
In respect of the mechanism of carbapenem resistance in A. 
baumannii, it was reported previously that resistance was due 
to OXA-23 enzymes; metallo-β-lactamases (blaVIM-2) were also 
found in some South African isolates.16  
Internationally, the prevalence of oxacillin-resistant S. 
aureus (ORSA) varies greatly by region, site of infection and 
whether the infection is of nosocomial or community onset. 
Previous studies4 of S. aureus isolates from blood cultures 
which included hospitalised patients from Johannesburg, 
reported 40% to be oxacillin-resistant. However, in this study 
no distinction was made between nosocomial and community-
acquired infections. Furthermore, geographical differences 
(29 - 46%) do exist in private practice. No resistance to 
teicoplanin, vancomycin or linezolid was detected and high 
rates of sensitivity to fusidic acid (97%), rifampicin (89%), 
gentamicin (88%) and trimethoprim/sulfamethoxazole (71%) 
were demonstrated. This suggests that a significant proportion 
of ORSA isolates may not be multi-resistant. In a previous 
study,17 including South African ORSA isolates (SENTRY-Asia-
Pacific), it was shown that 10% (40/394) of ORSA isolates 
from Johannesburg were not multi-resistant (resistance to less 
than 3 of the following antibiotics: erythromycin, tetracycline, 
gentamicin, chloramphenicol, rifampicin, ciprofloxacin and 
trimethoprim/sulfamethoxazole) and that the increase was 
attributed to the so-called British epidemic methicillin-resistant 
S. aureus (EMRSA) clone (resistance to erythromycin and 
ciprofloxacin only), in this case being EMRSA-16 and not 
EMRSA-15. Further investigations are warranted to confirm 
this trend.  Therefore, in contrast to serious Gram-negative 
infections, several empirical treatment options do exist for 
ORSA infections. 
Tigecycline, the first agent of the new broad-spectrum class 
of glycylcyclines, has been shown to have excellent activity 
against Gram-negative pathogens including ESBL-producing 
isolates, Acinetobacter spp. including carbapenem-resistant 
isolates, and Stenothrophomonas maltophilia,18 as well as Gram-
positive bacteria including ORSA.19 In our study susceptibility 
to this new antibiotic was not determined. In future, 
surveillance should also be extended to aminoglycosides 
among the fermentative Enterobacteriaceae, and polymyxin 
and aztreonam among isolates of P. aeruginosa and A. 
baumannii. Clindamycin and erythromycin susceptibility in S. 
aureus should also be reported.
The study clearly has several limitations and also highlights 
some problems. The study was performed in private 
practice in South Africa and therefore the relevance on a 
wider geographical scale is less clear. Typically in routine 
clinical laboratory practice, susceptibility testing of the study 
isolates was not performed at a single site, nor was uniform 
methodology used. Other limitations include the low numbers 
of isolates tested in some smaller centres and a lack of 
distinction between community and hospital acquisition. No 
clinical information was documented relating to colonisation 
or clinical significance; this includes the impact of resistance on 
outcome. Typing of isolates was not performed. It is therefore 
uncertain whether cross-infection or clonal spread may have 
occurred to possibly account for the differences in resistance 
rates in different localities. 
Additional problems highlighted in this study include the 
lack of standardisation in detection of glycopeptide resistance 
among isolates of S. aureus. Another problem is the lack of 
standard criteria for determination of ESBL production in 
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Enterobacter spp. in which production of de-repressed AMP-C 
β-lactamase enzymes can interfere with clavulanate synergy 
tests. In addition, concomitant ESBL production as described 
in E. aerogenes may be present.13 To detect such cases, Pitout et 
al.20 described a modified double disc test that was not utilised 
in participating laboratories. Overreporting of ESBL production 
in our study is also possible as 3 laboratories used Vitek 2, 
which has shown false-positive ESBL results with chromosomal 
K1 β-lactamase hyperproduction among Klebsiella species.21 
With all the diversity of ESBLs, appropriate testing among 
Enterobacteriaceae in routine clinical practice has become 
very complex. However, the results of the study should serve 
as the basis for comparing changes in resistance patterns as 
surveillance continues over time. 
In conclusion, there were significant regional differences 
in antibiotic resistance patterns in South Africa, and accurate 
surveillance of regional centres and preferably individual 
private hospitals, even at unit level, is necessary to optimise 
empirical antibiotic treatment for bacteraemic infections. 
Based on the results for K. pneumoniae, with the carbapenems 
currently the only empirical treatment option, antibiotic 
susceptibility patterns would also need close monitoring. The 
very high levels of antibiotic resistance prevalent throughout 
the study period in bloodstream isolates of P. aeruginosa and A. 
baumannii are of great concern as limited therapeutic options 
threaten the successful management of these infections, 
particularly in critically ill patients. No currently available 
single agent tested had adequate activity to be regarded as 
a suitable empirical option as monotherapy when either 
pseudomonal or Acinetobacter bacteraemia/septicaemia is 
suspected. Combination therapy is therefore advocated until 
susceptibility results are available, with the choice dictated by 
geographical and/or hospital-specific susceptibility patterns. 
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